L. Talarico, G. Chen, and R. Pazdur, Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, J Clin Oncol, vol.22, issue.22, pp.4626-4657, 2004.

K. C. Sokol, J. F. Knudsen, and M. M. Li, Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management1, J Clin Pharm Ther, vol.32, issue.2, pp.169-75, 2007.

P. N. Lara, R. Higdon, N. Lim, K. Kwan, M. Tanaka et al., Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment, J Clin Oncol, vol.19, issue.6, pp.1728-1761, 2001.

M. Puts, J. Monette, V. Girre, B. Costa-lima, C. Wolfson et al., Potential Medication Problems in Older Newly Diagnosed Cancer Patients in Canada during Cancer Treatment. Drugs Aging, vol.27, pp.559-72, 2010.

L. Balducci, D. Goetz-parten, and M. A. Steinman, Polypharmacy and the management of the older cancer patient, Ann Oncol, vol.24, issue.suppl_7, pp.36-40, 2013.

J. Li, M. Zhao, P. He, M. Hidalgo, and S. D. Baker, Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Cancer Res, vol.13, pp.3731-3738, 2007.

V. Wauthier, R. Verbeeck, and B. Calderon, The Effect of Ageing on Cytochrome P450

, Enzymes: Consequences for Drug Biotransformation in the Elderly, Curr Med Chem, vol.14, issue.7, pp.745-57, 2007.

E. A. Sotaniemi, A. J. Arranto, O. Pelkonen, and M. Pasanen, Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions

, Clin Pharmacol Ther, vol.61, issue.3, pp.331-340, 1997.

M. M. Cotreau, L. L. Von-moltke, and D. J. Greenblatt, The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates, Clin Pharmacokinet, vol.44, issue.1, pp.33-60, 2005.

B. D. Smith, G. L. Smith, A. Hurria, G. N. Hortobagyi, and T. A. Buchholz, Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation, J Clin Oncol. 27 avr, vol.27, issue.17, pp.2758-65, 2009.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al.,

, Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol. 1 août, vol.29, issue.25, pp.3457-65, 2011.

, Etat des lieux et perspectives et perspectives en onco-gériatrie, 2009.

A. Hurria, T. Wildes, S. L. Blair, I. S. Browner, H. J. Cohen et al., Senior adult oncology, version 2.2014: clinical practice guidelines in oncology, J Natl Compr Cancer Netw JNCCN. janv, vol.12, issue.1, pp.82-126, 2014.

, Plan Cancer, 2003.

, Plan Cancer, 2009.

, Plan Cancer, 2014.

A. Hurria, H. J. Cohen, and M. Extermann, Geriatric Oncology Research in the Cooperative Groups: A Report of a SIOG Special Meeting, J Geriatr Oncol. 1 juin, vol.1, issue.1, pp.40-44, 2010.

A. Hurria, S. G. Mohile, and W. Dale, Research Priorities in Geriatric Oncology: Addressing the Needs of an Aging Population, J Natl Compr Cancer Netw JNCCN. févr, vol.10, issue.2, pp.286-294, 2012.

L. Talarico, G. Chen, and R. Pazdur, Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, J Clin Oncol, vol.22, issue.22, pp.4626-4657, 2004.

K. S. Scher and A. Hurria, Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress, J Clin Oncol, vol.30, issue.17, pp.2036-2044, 2012.

A. Daste, C. Chakiba, C. Domblides, M. Gross-goupil, A. Quivy et al., Targeted therapy and elderly people: A review, Eur J Cancer. 1 déc, vol.69, pp.199-215, 2016.

, Studies in support of special populations: geriatrics, European Medicines Agency. CH Topic E7, 1994.

D. Sur,

L. Balducci, Geriatric oncology: challenges for the new century, Eur J Cancer. 1 sept, vol.36, issue.14, pp.1741-54, 2000.

A. Surbone, M. Kagawa-singer, C. Terret, and L. Baider, The illness trajectory of elderly cancer patients across cultures: SIOG position paper, Ann Oncol. 1 avr, vol.18, issue.4, pp.633-641, 2007.

L. Balducci and M. Extermann, Management of Cancer in the Older Person: A Practical Approach, The Oncologist. 6 janv, vol.5, issue.3, pp.224-261, 2000.

M. Bretagne, P. Boudou-rouquette, O. Huillard, A. Thomas-schoemann, and A. Chahwakilian,

G. Orvoen, Inhibiteurs de tyrosine kinase ciblant l'angiogenèse et sujets âgés : tolérance, évaluation pré-thérapeutique et gestion des effets indésirables, Bull Cancer (Paris). 1 mars, vol.103, issue.3, pp.259-72, 2016.

S. D. Baker, L. P. Schaik-rhn-van,-rivory, . Tije-aj-ten, K. Dinh, and W. J. Graveland, Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients, Clin Cancer Res. 15 déc, vol.10, issue.24, pp.8341-50, 2004.

A. Quivy, A. Daste, A. Harbaoui, S. Duc, J. Bernhard et al., Optimal management of renal cell carcinoma in the elderly: a review, Clin Interv Aging, vol.8, pp.433-475, 2013.

A. Thomas-schoemann, B. Blanchet, C. Bardin, G. Noé, P. Boudou-rouquette et al., Drug interactions with solid tumour-targeted therapies, Crit Rev Oncol Hematol. 1 janv, vol.89, issue.1, pp.179-96, 2014.

A. G. Pallis, C. Fortpied, U. Wedding, M. C. Van-nes, B. Penninckx et al., EORTC elderly task force position paper: Approach to the older cancer patient, Eur J Cancer. 1 juin, vol.46, issue.9, pp.1502-1515, 2010.

M. Extermann and A. Hurria, Comprehensive Geriatric Assessment for Older Patients With Cancer, J Clin Oncol. 10 mai, vol.25, issue.14, pp.1824-1855, 2007.

I. Carreca, L. Balducci, and M. Extermann, Cancer in the older person, Cancer Treat Rev. 1 août, vol.31, issue.5, pp.380-402, 2005.

A. E. Stuck, A. L. Siu, G. D. Wieland, L. Z. Rubenstein, and J. Adams, Comprehensive geriatric assessment: a meta-analysis of controlled trials. The Lancet, vol.342, pp.1032-1038, 1993.

S. Katz, T. D. Downs, H. R. Cash, and R. C. Grotz, Progress in Development of the Index of ADL

, The Gerontologist. 1 mars, vol.10, issue.1_Part_1, pp.20-30, 1970.

M. P. Lawton and E. M. Brody, Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. The Gerontologist, vol.9, pp.179-86, 1969.

L. Repetto, L. Fratino, R. A. Audisio, A. Venturino, W. Gianni et al.,

, Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study, J Clin Oncol. 15 janv, vol.20, issue.2, pp.494-502, 2002.

M. Extermann, J. Overcash, G. H. Lyman, J. Parr, and L. Balducci, Comorbidity and functional status are independent in older cancer patients, J Clin Oncol Off J Am Soc Clin Oncol. avr, vol.16, issue.4, pp.1582-1589, 1998.

A. Hurria, S. Mohile, A. Gajra, H. Klepin, H. Muss et al.,

, Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer, J Clin Oncol. 10 juill, vol.34, issue.20, pp.2366-71, 2016.

M. E. Tinetti, M. Speechley, and S. F. Ginter, Risk Factors for Falls among Elderly Persons Living in the Community, N Engl J Med. 29 déc, vol.319, issue.26, pp.1701-1708, 1988.

S. Mathias, U. S. Nayak, and B. Isaacs, Balance in elderly patients: the « get-up and go » test

, Arch Phys Med Rehabil. juin, vol.67, issue.6, pp.387-396, 1986.

K. E. Schmader, J. T. Hanlon, C. F. Pieper, R. Sloane, C. M. Ruby et al., Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly, Am J Med. 15 mars, vol.116, issue.6, pp.394-401, 2004.

C. M. Williams, Using Medications Appropriately in Older Adults, Am Fam Physician, vol.66, issue.10, p.1917, 2002.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chronic Dis. 1 janv, vol.40, issue.5, pp.373-83, 1987.

P. A. Parmelee, P. D. Thuras, I. R. Katz, and M. P. Lawton, Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population, J Am Geriatr Soc, vol.43, issue.2, pp.130-137, 1995.

W. D. Dewys, C. Begg, P. T. Lavin, P. R. Band, J. M. Bennett et al., Prognostic effect of weight loss prior tochemotherapy in cancer patients, Am J Med, vol.69, issue.4, pp.491-498, 1980.

J. I. Wallace, R. S. Schwartz, A. Z. Lacroix, R. F. Uhlmann, and R. A. Pearlman, Involuntary Weight Loss in Older Outpatients: Incidence and Clinical Significance, J Am Geriatr Soc, vol.43, issue.4, pp.329-366, 1995.

M. W. Reynolds, L. Fredman, P. Langenberg, J. Magaziner, and . Weight, Weight Change, and Mortality in a Random Sample of Older Community-Dwelling Women, J Am Geriatr Soc, vol.47, issue.12, pp.1409-1423, 1999.

A. B. Newman, D. Yanez, T. Harris, A. Duxbury, P. L. Enright et al., Weight Change in Old Age and its Association with Mortality, J Am Geriatr Soc, vol.49, issue.10, pp.1309-1327, 2001.

B. Vellas, Y. Guigoz, P. J. Garry, F. Nourhashemi, D. Bennahum et al., The mini nutritional assessment (MNA) and its use in grading the nutritional state of elderly patients, Nutrition. 1 févr, vol.15, issue.2, pp.116-138, 1999.

J. Toliusiene and V. Lesauskaite, The nutritional status of older men with advanced prostate cancer and factors affecting it, Support Care Cancer, vol.12, issue.10, pp.716-725, 2004.

M. F. Folstein, S. E. Folstein, and P. R. Mchugh, Mini-mental state": A practical method for

D. R. Royall, D. V. Espino, M. J. Polk, R. Verdeja, S. Vale et al., Validation of a Spanish translation of the CLOX for use in Hispanic samples: the Hispanic EPESE study, Int J Geriatr Psychiatry, vol.18, issue.2, pp.135-176, 2003.

P. Cowppli-bony, C. Fabrigoule, L. Letenneur, K. Ritchie, A. Alpérovitch et al.,

, Le test des 5 mots : validité dans la détection de la maladie, 2008.

D. Sur,

J. A. Yesavage, T. L. Brink, T. L. Rose, O. Lum, V. Huang et al., Development and validation of a geriatric depression screening scale: A preliminary report, J Psychiatr Res. 1 janv, vol.17, issue.1, pp.37-49, 1982.

L. G. Marc, P. J. Raue, and M. L. Bruce, Screening Performance of the Geriatric Depression Scale (GDS-15) in a Diverse Elderly Home Care Population, Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry, vol.16, issue.11, pp.914-935, 2008.

J. P. Clément, R. F. Nassif, J. M. Léger, and F. Marchan,

, L'Encephale. avr, vol.23, issue.2, pp.91-100, 1997.

L. Balducci, Geriatric oncology: challenges for the new century, Eur J Cancer. 1 sept, vol.36, issue.14, pp.1741-54, 2000.

P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Curé et al., Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

C. A. Bellera, M. Rainfray, S. Mathoulin-pélissier, C. Mertens, F. Delva et al., Disponible sur, PLoS ONE, vol.9, issue.12

, Screening older cancer patients: first evaluation of the G-8 geriatric screening tool, Ann Oncol. 1 août, vol.23, issue.8, pp.2166-72, 2012.

L. Decoster, K. Van-puyvelde, S. Mohile, U. Wedding, U. Basso et al., Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations ?, Ann Oncol Off J Eur Soc Med Oncol. févr, vol.26, issue.2, pp.288-300, 2015.

S. G. Mohile, W. Dale, M. R. Somerfield, M. A. Schonberg, C. M. Boyd et al.,

, Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology, J Clin Oncol. 21 mai, vol.36, issue.22, pp.2326-2373, 2018.

C. Buske, M. Hutchings, M. Ladetto, V. Goede, U. Mey et al.,

, Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma, Ann Oncol. 1 mars, vol.29, issue.3, pp.544-62, 2018.

, Frailty as a Predictor | SIOG

E. Paillaud, P. Soubeyran, P. Caillet, T. Cudennec, E. Brain et al., Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey, Eur J Cancer, vol.103, pp.61-69, 2018.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, Cancer, vol.118, issue.13, pp.3377-86, 2012.

P. Soubeyran, M. Fonck, C. Blanc-bisson, J. Blanc, J. Ceccaldi et al., Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer, J Clin Oncol. 16 avr, vol.30, issue.15, pp.1829-1863, 2012.

S. Hoppe, M. Rainfray, M. Fonck, L. Hoppenreys, J. Blanc et al., Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy, J Clin Oncol. 23 sept, vol.31, issue.31, pp.3877-82, 2013.

A. Ramjaun, M. O. Nassif, S. Krotneva, A. R. Huang, and A. N. Meguerditchian, Improved targeting of cancer care for older patients: A systematic review of the utility of comprehensive geriatric assessment, J Geriatr Oncol. 1 juill, vol.4, issue.3, pp.271-81, 2013.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell. 4 mars, vol.144, pp.646-74, 2011.

C. R. Chong and P. A. Jänne, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat Med. nov, vol.19, issue.11, pp.1389-400, 2013.

I. J. Fidler and L. M. Ellis, The implications of angiogenesis for the biology and therapy of cancer metastasis, Cell, vol.79, issue.2, pp.185-193, 1994.

N. Ferrara, H. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nat Med. juin

C. J. Wikstrand and D. D. Bigner, Prognostic Applications of the Epidermal Growth Factor Receptor and Its Ligand, Transforming Growth Factor-?, JNCI J Natl Cancer Inst. 3 juin, vol.90, issue.11, pp.799-813, 1998.

A. Ardizzoni and M. Tiseo, Combination of Target Agents: Challenges and Opportunities, J Thorac Oncol. 1 mai, vol.2, issue.5, pp.4-6, 2007.

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med. 22 août, vol.369, issue.8, pp.722-753, 2013.

T. K. Choueiri, F. Schutz, Y. Je, and J. E. Rosenberg,

, Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials, J Clin Oncol. 29 mars, vol.28, issue.13, pp.2280-2285, 2010.

M. Locatelli, C. Criscitiello, A. Esposito, I. Minchella, A. Goldhirsch et al., QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review, Target Oncol. 1 mars, vol.10, issue.1, pp.27-43, 2015.

S. Segaert and E. Van-cutsem, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Ann Oncol. 1 sept, vol.16, issue.9, pp.1425-1458, 2005.

B. Mclellan and H. Kerr, Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib, Dermatol Ther, vol.24, issue.4, pp.396-400, 2011.

M. C. Houdu and C. Tournigand, Toxicités digestives des thérapeutiques ciblées, Lett Cancérologue. mars, vol.12, issue.3, p.5, 2013.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet, vol.9, pp.449-56, 2008.

J. Baselga, M. Campone, M. Piccart, H. A. Burris, H. S. Rugo et al., Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer, N Engl J Med. 9 févr, vol.366, issue.6, pp.520-529, 2012.

R. Sabatier, J. C. Eymard, J. Walz, J. L. Deville, H. Narbonne et al., Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?, Ann Oncol. 1 mars, vol.23, issue.3, pp.714-735, 2012.

S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic et al.,

A. Pharmacokinetic, Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer, J Clin Oncol. 1 janv, vol.24, issue.1, pp.25-35, 2006.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma


G. D. Demetri, A. T. Oosterom, . Van, C. R. Garrett, M. E. Blackstein et al.,

, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet, vol.368, pp.1329-1367, 2006.

R. Eric, D. Laetitia, R. Jean-luc, Y. , B. Ivan et al., Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, N Engl J Med, vol.13, 2011.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med. 11 janv, vol.356, issue.2, pp.115-139, 2007.

T. E. Hutson, R. M. Bukowski, B. I. Rini, M. E. Gore, J. M. Larkin et al., Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma, Br J Cancer. mars, vol.110, issue.5, pp.1125-1157, 2014.

A. Brunello, U. Basso, C. Sacco, T. Sava, D. Vivo et al., Safety and activity of sunitinib in elderly patients (?70 years) with metastatic renal cell carcinoma: a multicenter study, Ann Oncol. 1 févr, vol.24, issue.2, pp.336-378, 2013.

S. George, J. Y. Blay, P. G. Casali, A. L. Cesne, P. Stephenson et al., Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure, Eur J Cancer. 1 juill, vol.45, issue.11, pp.1959-68, 2009.

S. M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., , pp.43-9006

, Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Res, vol.64, pp.7099-109, 2004.

B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med. 11 janv, vol.356, issue.2, pp.125-159, 2007.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, N Engl J Med. 24 juill, vol.359, issue.4, pp.378-90, 2008.

M. S. Brose, C. M. Nutting, B. Jarzab, R. Elisei, S. Siena et al., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet Lond Engl. 26 juill, vol.384, issue.9940, pp.319-347, 2014.

T. Eisen, S. Oudard, C. Szczylik, G. Gravis, H. Heinzer et al., Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial, JNCI J Natl Cancer Inst, vol.100, issue.20, pp.1454-63, 2008.

R. M. Bukowski, W. M. Stadler, D. F. Mcdermott, J. P. Dutcher, J. J. Knox et al., Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program, Oncology, vol.78, issue.5-6, pp.340-347, 2010.

G. Procopio, J. Bellmunt, J. Dutcher, S. Bracarda, J. Knox et al., Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis, Br J Cancer. févr, vol.108, issue.2, pp.311-319, 2013.

H. Wong, Y. F. Tang, T. Yao, J. Chiu, R. Leung et al., The Outcomes and Safety of

, Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC), The Oncologist. 12 janv, vol.16, issue.12, pp.1721-1729, 2011.

D. Costanzo, G. G. Tortora, R. , D. Luca, M. et al.,

, Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma, Med Oncol. 10 janv, vol.30, issue.1, p.446, 2013.

M. Morimoto, K. Numata, M. Kondo, H. Hidaka, J. Takada et al., Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib, Hepatol Res, vol.41, issue.4, pp.296-302, 2011.

C. N. Sternberg, I. D. Davis, J. Mardiak, C. Szczylik, E. Lee et al.,

, Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

W. T. Van-der-graaf, J. Blay, S. P. Chawla, D. Kim, B. Bui-nguyen et al., J Clin Oncol. 25 janv, vol.28, issue.6, pp.1061-1069, 2010.

, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. The Lancet, vol.379, pp.1879-86, 2012.

D. Garbay, R. G. Maki, J. Y. Blay, N. Isambert, P. Neumann et al., Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival, Ann Oncol. 1 juill, vol.24, issue.7, pp.1924-1954, 2013.

L. Mourey, A. Ravaud, L. Digue, B. Cabarrou, C. A. Gomez-roca et al.,

, 898PVOTRAGE study pazopanib in a population of "frail" elderly patients after geriatric assessment: A phase I study with geriatric criteria, Ann Oncol, issue.1, 2018.

S. M. Wilhelm, J. Dumas, L. Adnane, M. Lynch, C. A. Carter et al., Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, Int J Cancer, vol.129, issue.1, pp.245-55, 2011.

A. Grothey, E. V. Cutsem, A. Sobrero, S. Siena, A. Falcone et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet, janv, vol.26, issue.9863, pp.303-315, 2013.

H. K. Sanoff and R. M. Goldberg, How we treat metastatic colon cancer in older adults, J Geriatr Oncol, vol.4, issue.4, pp.295-301, 2013.

G. D. Demetri, P. Reichardt, Y. Kang, J. Blay, P. Rutkowski et al., Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebocontrolled phase 3 trial (GRID), Lancet, issue.9863, p.381

D. Sur,

S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, R. Chester et al., ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration, Cancer Res. 15 août, vol.62, issue.16, pp.4645-55, 2002.

S. A. Wells, B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin et al., Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial, J Clin Oncol, vol.30, issue.2, pp.134-175, 2012.

M. Massicotte, I. Borget, S. Broutin, V. E. Baracos, S. Leboulleux et al., Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study, J Clin Endocrinol Metab. 1 juin, vol.98, issue.6, pp.2401-2409, 2013.

C. Gridelli, S. Novello, N. Zilembo, A. Luciani, A. G. Favaretto et al., Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients, J Thorac Oncol, vol.1, 2014.

M. Schlumberger, M. Tahara, L. J. Wirth, B. Robinson, M. S. Brose et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med. 12 févr, vol.372, issue.7, pp.621-651, 2015.

M. S. Brose, F. P. Worden, K. L. Newbold, M. Guo, and A. Hurria, Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial, J Clin Oncol. 14 juin, vol.35, issue.23, pp.2692-2701, 2017.

M. L. Johnson, C. S. Sima, J. Chaft, P. K. Paik, W. Pao et al., Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas, Cancer. 15 janv, vol.119, issue.2, pp.356-62, 2013.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. 1 mars, vol.13, issue.3, pp.239-285, 2012.

T. S. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma, N Engl J Med. 3 sept, vol.361, issue.10, pp.947-57, 2009.

L. Crinò, F. Cappuzzo, P. Zatloukal, M. Reck, M. Pesek et al., Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study, J Clin Oncol. 10 sept, vol.26, issue.26, pp.4253-60, 2008.

A. Inoue, K. Kobayashi, K. Usui, M. Maemondo, S. Okinaga et al., First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy, J Clin Oncol. 17 févr, vol.27, issue.9, pp.1394-400, 2009.

M. Maemondo, Y. Minegishi, A. Inoue, K. Kobayashi, M. Harada et al., First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study, J Thorac Oncol. 1 sept, vol.7, issue.9, pp.1417-1439, 2012.

K. Asami, T. Koizumi, K. Hirai, S. Ameshima, A. Tsukadaira et al., Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study, Clin Lung Cancer, vol.12, issue.6, pp.387-92, 2011.

K. Takahashi, H. Saito, Y. Hasegawa, M. Ando, M. Yamamoto et al., First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901, Cancer Chemother Pharmacol, vol.74, issue.4, pp.721-728, 2014.

S. B. Yellen, D. F. Cella, and W. T. Leslie, Age and Clinical Decision Making in Oncology Patients

, JNCI J Natl Cancer Inst. 7 déc, vol.86, issue.23, pp.1766-70, 1994.

J. Yang, Y. Wu, M. Schuler, M. Sebastian, S. Popat et al., Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma

L. , Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol. 1 févr, vol.16, issue.2, pp.141-51, 2015.

T. S. Mok, Y. Wu, M. Ahn, M. C. Garassino, H. R. Kim et al., Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, N Engl J Med, vol.16, issue.7, pp.629-669, 2017.

J. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong et al.,

, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med, issue.18, 2017.

D. Sur,

C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu et al., Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med. 28 déc, vol.355, issue.26, pp.2733-2776, 2006.

J. P. Crown, H. A. Burris, F. Boyle, S. Jones, M. Koehler et al., Pooled analysis of diarrhea events in patients with cancer treated with lapatinib, Breast Cancer Res Treat, vol.112, issue.2, pp.317-342, 2008.

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med. 20 juin, vol.368, issue.25, pp.2385-94, 2013.

R. P. Dematteo, K. V. Ballman, C. R. Antonescu, R. G. Maki, P. Pisters et al.,

, Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST), Lancet. 28 mars, vol.373, issue.9669, pp.1097-104, 2009.

P. G. Casali, L. Cesne, A. , P. Velasco, A. Kotasek et al.,

, Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial, J Clin Oncol. 20 mai, vol.31, issue.15_suppl, pp.10500-10500, 2013.

H. Joensuu, M. Eriksson, K. S. Hall, J. T. Hartmann, D. Pink et al., One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial, JAMA. 28 mars, vol.307, issue.12, pp.1265-72, 2012.

D. , A. L. Ponzetti, A. Lista, P. Bombaci, S. Palesandro et al., Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST), J Clin Oncol. 20 mai, vol.29, issue.15_suppl, pp.20514-20514, 2011.

S. Farag, F. Van-coevorden, E. Sneekes, D. J. Grunhagen, A. Reyners et al., Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity -A retrospective multicentre study in a large cohort of GIST patients, Eur J Cancer, vol.86, pp.318-343, 2017.

R. J. Motzer, C. H. Barrios, T. M. Kim, S. Falcon, T. Cosgriff et al., Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma, J Clin Oncol. 1 sept, vol.32, issue.25, pp.2765-72, 2014.

C. Porta, E. Calvo, M. A. Climent, U. Vaishampayan, S. Osanto et al., Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial, Eur Urol. avr, vol.61, issue.4, pp.826-859, 2012.

K. I. Pritchard, H. A. Burris, Y. Ito, H. S. Rugo, S. Dakhil et al., Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2, Clin Breast Cancer. 1 déc, vol.13, issue.6, pp.421-432, 2013.

, Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults, American Geriatrics Society, vol.67, issue.4, pp.674-94, 2019.

I. A. Scott, S. N. Hilmer, E. Reeve, K. Potter, D. L. Couteur et al., Reducing Inappropriate Polypharmacy: The Process of Deprescribing, JAMA Intern Med. 1 mai, vol.175, issue.5, pp.827-861, 2015.

, Serment d'Hippocrate

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, que je sois déshonoré et méprisé si j'y manque